The Integrated Forecasting and Analysis Tool   Login Now

Sepracor

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Sepracor are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Sepracor, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Sepracor 1 Lunesta eszopiclone GABA agonist 565 601   6%     2 Xopenex levalbuterol hydrocholoride Beta 2 agonist 543 487   (10%)     3 Xopenex HFA levalbuterol tartrate Beta 2 agonist 41 75   83%       Note: Shaded Cells

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Sepracor 1 SEP-0002093 Central Nervous System Anti-epileptics Iminostilbene Phase III   2 SEP-225289 Central Nervous System Anti-depressants Noradrenaline, dopamine & 5HT reuptake inhibitor Phase II   3 XRP1526 Respiratory Other bronchodilators Beta 2 agonist & corticosteroid Phase II

DEALS - Selected Company Deals

Rank Deal Date Deal Type Product Status on Deal Date Deal Partner/ Product Source Deal Value Sepracor 1 Jan 2008 In-licensed Omnaris AQ Nasal Spray Approved Nycomed 215   =1 Jan 2008 In-licensed Alvesco Approved Nycomed 215   3 Jan 2008 In-licensed SEP-0002093 Phase III Bial 175

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Sepracor   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 2,103 2,103        PE Ratio (diluted) - Normalised (x) (59.7) 13.2        Valuing the Enterprise        Enterprise Value 1,935 1,935        Free Cash Flow (Pre-Dividends) (21) 178        FCF Yield (%) (1.1%) 9.2%    Forecast Financials   Income Statement      Total Revenues 801 1,183      Cost of Goods Sold (67) (105)      S,G & A (627) (764)      R&D (145) (163)      Other Income/ Expense - Net 0 0      Associate/ Equity Affiliate Income (1) 0      EBIT - Normalised (38) 150      Net Interest & Financial Items 4 24      Pre-tax Profits - Normalised (34) 175      Exceptionals 18 -      Income Before Taxes (16) 175      Tax 0 (4)      Tax Rate (%) 1.0% 2.1%      Net Income - Reported (16) 171      Net Income - Normalised (34) 171     Per Share Data      EPS - Diluted (0.15) 1.48      EPS - Basic (0.15) 1.63      EPS - Normalised (diluted) (0.33) 1.48      EPS - Normalised (basic) (0.33) 1.63      Avg. Shares Outstanding - Diluted 104.8 115.5      Avg. Shares Outstanding - Basic 104.8 104.9      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry   (Sepracor)   12-May-2008 Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination   (Sepracor)   01-May-2008 OMNARIS(TM) Nasal Spray Now Available by Prescription for Patients with Seasonal and Perennial Allergies   (Sepracor)   17-Apr-2008 Sepracor Presents Safety Data on OMNARIS(TM) AQ and OMNARIS(TM) HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology (AAAAI)   (Sepracor)   17-Mar-2008 Sepracor Presents OMNARIS(TM) HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology (AAAAI)   (Sepracor)   17-Mar-2008 FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria   (UCB)   19-Feb-2008 FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria   (Sanofi-Aventis)   19-Feb-2008 BROVANA(TM) Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference   (Sepracor)   25-Oct-2007 New Prescription Allergy Treatment XYZAL® (levocetirizine dihydrochloride) Now Available for Fall Allergy Season in the USA   (UCB)   02-Oct-2007 New Prescription Allergy Treatment XYZAL® (Levocetirizine Dihydrochloride) Now Available for Fall Allergy Season   (Sanofi-Aventis)   02-Oct-2007 Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment   (Eisai)   27-Jul-2007 Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe   (Sepracor)   27-Jul-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Sepracor (-)-Pantoprazole (-)-pantoprazole   (+)-Hydroxyitraconazole (+)-hydroxyitraconazole   2R,4S-Itraconazole (2R,4S)-itraconazole   5-HT2A Antagonist Program -   Allegra/Telfast fexofenadine   Alvesco ciclesonide   Alvesco Inhalation Solution ciclesonide   Astelin azelastine   Brovana (R,R)-formoterol   Brovana/Ciclesonide arformoterol tartrate & ciclesonide   Clarinex desloratadine   Clarinex-D desloratadine & pseudoephedrine   Desmethylvenlafaxine desmethylvenlafaxine   Hydroxy bupropion hydroxy bupropion   Ipratropium ipratropium   Long-Acting Beta-Agonists -   Lunesta eszopiclone   M1 Agonist Program -   Nefazodone metabolite -   Omnaris AQ Nasal Spray ciclesonide   Omnaris HFA ciclesonide   R-Bupropion (R)-bupropion   R-Fluoxetine (R)-fluoxetine   R-Ketoprofen (R)-ketoprofen   R-Ondansetron (R)-ondansetron   R-Sibutramine (R)-sibutramine   S-Amlodipine levamlodipine malate   S-Doxazosin (S)-doxazosin   SEP-0002093 eslicarbazepine acetate   SEP-0225213 -   SEP-0226332 -   SEP-167864 -   SEP-174559 desmethylzopiclone   SEP-200421 -   SEP-200657 -   SEP-225289 -   SEP-225382 -   SEP-225425 -   SEP-225432 -   SEP-225441 -   SEP-226330 -   SEP-227162 -   SEP-227900 -   S-Fluoxetine (S)-fluoxetine   S-Lansoprazole (S)-lansoprazole   Soltara tecastemizole   S-Oxybutynin esoxybutynin   S-Salmeterol (S)-salmeterol   S-Sibutramine (S)-sibutramine   Ticalopride (+)-norcisapride   Xopenex levalbuterol hydrocholoride   Xopenex HFA levalbuterol tartrate   Xopenex/Ipratropium levalbuterol & ipratropium   XRP1526 ciclesonide & formoterol   Xyzal levocetirizine

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 14:20:03 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd